Granulomatous hepatitis as a late complication of BCG immunotherapy.
A case of BCG-induced granulomatous hepatitis, which developed 1 1/2 years after BCG immunotherapy for recurrent malignant melanoma, is described to document the development of this disease entity as a potential late complication of BCG immunotherapy. The clinical implications of the late development of BCG-induced granulomatous hepatitis, use of immunosuppressive chemotherapy, and possible alternatives for BCG in intratumor immunotherapy are discussed.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001500:BCG Vaccine / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006099:Granuloma / Q000209:etiology / Q000473:pathology; D006505:Hepatitis / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007167:Immunotherapy / Q000009:adverse effects*; D008107:Liver Diseases / Q000209:etiology; D008545:Melanoma / Q000628:therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007166:Immunosuppressive Agents